![Close-up of photo of an infant showing the bottom half of the face with atopic dermatis rash](/static/baby-img-5639e4f3c7e8cd8699354e828b91aad7.jpg)
Refusing to stop at
Apogee is seeking to reshape the current standard of care for inflammatory and immune diseases because we believe people living with these diseases deserve the best possible treatment.
Our pipeline of differentiated antibody therapeutics targets well-established biological drivers and development pathways, with an initial focus on making impactful advancements in the treatment of atopic dermatitis and chronic obstructive pulmonary disease.
People first, always